Vivo is skipping the S40 series and heading straight to the S50 lineup, and there’s an interesting reason behind it. Fresh ...
The investigator-initiated study will evaluate Create's MT-302 plus chemo with or without standard immunotherapy and anti-HER2 therapy in the first-line setting.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback